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Background. Research aimed at developing vaccines against infectious diseases generally seeks to induce robust immune
responses to immunodominant antigens. This approach has led to a number of efficient bacterial and viral vaccines, but it has yet
to do so for parasitic pathogens. For malaria, a disease of global importance due to infection by Plasmodium protozoa,
immunization with radiation-attenuated sporozoites uniquely leads to long lasting sterile immunity against infection. The
circumsporozoite protein (CSP), an important component of the sporozoite’s surface, remains the leading candidate antigen for
vaccines targeting theparasite’s pre-erythrocyticstages. Difficulties indevelopingCSP-based vaccines that reproduce the levels of
protection afforded by radiation-attenuated sporozoites have led us to question the role of CSP in the acquisition of sterile
immunity. We have used a parasite transgenic for the CSP because it allowed us to test whether a major immunodominant
Plasmodium antigen is indeed needed for the induction of sterile protective immunity against infection. Methodology/Main
Findings. We employed a P. berghei parasite line that expresses a heterologous CSP from P. falciparum in order to assess the role
of the CSP in the protection conferred by vaccination with radiation-attenuated P. berghei parasites. Our data demonstrated that
sterile immunity could be obtained despite the absence of immune responses specific to the CSP expressed by the parasite used
for challenge. Conclusions. We conclude that other pre-erythrocytic parasite antigens, possibly hitherto uncharacterised, can be
targeted to induce sterile immunity against malaria. From a broader perspective, our results raise the question as to whether
immunodominant parasite antigens should be the favoured targets for vaccine development.
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to the Circumsporozoite Protein. PLoS ONE 2(12): e1371. doi:10.1371/journal.pone.0001371
INTRODUCTION
An ideal target of vaccination against malaria would be the initial
PE stages of the infection, i.e. the sporozoite and the hepatic
phase. Sporozoites inoculated by the mosquito can only invade
and develop within hepatocytes to generate merozoites that, once
released in the blood stream, initiate the pathogenic erythrocytic
phase. Effective inhibition of this obligatory and transient phase of
the life cycle would prevent infection, disease, and reduce
transmission. Sterile immunity against PE stages is an all-or-none
phenomenon, since successful infection of a single hepatocyte
would lead to a patent blood infection. In humans, immunization
with large numbers of radiation-attenuated sporozoites remains
the only protocol that leads to the induction of sterile immunity
[1,2]. Subsequent investigations revealed a role for both humoral
and cellular immune responses targeting the sporozoite and the
infected hepatocyte, respectively
3. Until recently, only a few
antigens thought to be implicated in protection against the PE
stages had been identified (CSP, Liver Stage Antigens 1 & 3, and
the Thrombospondin Related Anonymous Protein)[3].
The dominant antibody responses directed against the antigenic
repetitive central domain of CSP in the vaccinated hosts [4], and
the ability of passively transferred CSP-specific CD8
+ and CD4
+ T
cell clones to fully protect against sporozoite challenge [5–7], have
led to consider the CSP as the most likely parasite antigen
implicated in the sterile protection induced by irradiated
sporozoites. Since the mid-1980s numerous experimental subunit
vaccines based solely or partially on CSP have been tried in naı ¨ve
volunteers and endemic residents [8]. However, when vaccination
trials using the latest and most advanced CSP-based formulation,
RTS,S, were conducted in endemic residents, the extent of the
sterile protection observed was moderate and transient in nature
[9–11]. The modest efficacies of this and other experimental CSP-
based vaccines, led us to question the importance of immune
responses against CSP in the induction and acquisition of sterile
protection. There are immunological and epidemiological data
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acquired protective responses. First, CSP-specific immune re-
sponses in naturally exposed humans were found to be poorly
predictive of protection [12]. Second, molecular epidemiological
observations suggested that immune responses to CSP do not exert
a strong selective pressure [13,14]. Third, analyses of immune
responses in a subset of volunteers protected by immunization with
irradiated sporozoites revealed that the predominant cellular
responses were directed at parasite antigens other than CSP [15].
For ethical reasons, proof for the involvement of CSP in sterile
protection can only be derived from animal models. Formal
demonstration of the role of CSP in the induction or sterile
immunity cannot be obtained by knock-out studies since the
protein is necessary for the development of infective sporozoites
[16]. Recent advances in transgenic technology afforded a means
to assess the actual contribution of CSP in the acquisition of sterile
immunity following immunization of mice with irradiated P. berghei
sporozoites. To this end, we used a recently described transgenic P.
berghei line, P. berghei [PfCS], whose CSP gene was replaced by that
of P. falciparum [17]. The P. berghei [PfCS] parasites had been
previously shown to produce functional infective sporozoites [17].
MATERIALS AND METHODS
Mice and Plasmodium parasites
BALB/cJ or [BALB/c6C57BL/6J] F1 mice were purchased from
Harlan Laboratories (Gannat, France), and were housed in a
pathogen-free rodent barrier facility. All experiments and
procedures were performed in compliance with institutional and
national guidelines. P. berghei ANKA cloned lines transfected either
with the P. falciparum CSP gene from the Welcome strain [17] or
with a GFP gene [18] both of which had been submitted to the
same selection procedure, were used to infect laboratory-bred
Anopheles stephensi mosquitoes. Sporozoites from the two parasite
lines were obtained by dissection of infected A. stephensi salivary
glands 17 to 21 days after the infective blood meal.
Immunization and challenge
Inorderto inducesterileimmunity inall the animals, BALB/cJ mice
were immunized with 12 000 rad-irradiated P. berghei sporozoites as
follows:onedoseof75 000sporozoitesfollowedbytwoboosterdoses
of 25 00 of P. berghei sporozoites on days 15 and 21. In [BALB/
c6C57BL/6] F1 mice immunisation was made with 3 injections of
10 000 P. berghei irradiated sporozoites at days 0, 15 and 21. Control
and mice irradiated sporozoites-immunized mice were challenged
intravenously with 5 000 P. berghei or P. berghei [PfCS] sporozoites.
Blood stage infection was determined by the presence of parasites in
Giemsa-stained blood smears prepared daily from days 3 to 10 post-
challenge, and parasitaemia was determined by counting the
number of infected red blood cells per 1000 erythrocytes.
Peptides
The following peptides were synthesized by one of us (GC): a)
peptidesthatcorrespond to therepeatregionofthe P.bergheiorthe P.
falciparum CS protein, (DPPPPNPN)2 and NANP50, respectively,
were used in ELISA as previously described [19–22]. Lyophilized
material was resuspended in sterile distilled water at 10 mg/ml,
aliquoted, and stored at - 20uC until use, b) long peptides that
spanned the NH2-terminal and COOH-terminal of the P. berghei
CSP, PbNt (GYGQNKSIQA QRNLNELCYN EGNDNKLYHV
LNSKNGKIYI RNTVNRLLAD APEGKKNEKK NEKIERN-
NKL K) and PbCt (NDDSYIPSAE KILEFVKQIR DSITEEW-
SQC NVTCGSGIRV RKRKGSNKKA EDLTLEDIDT EICK-
MDKCS), respectively, and c) long peptides that spanned the
NH2-terminal and COOH-terminal of the P. falciparum CSP, PfNt
(YQCYGSSSNT RVLNELNYDN AGTNLYNELE MNYYGK-
QENW YSLKKNSRSL GENDDGNNNN GDNGREGKDE
DKRDGNNEDN EKLRKPKHKK LKQPGDGNPD PNA) and
PfCt (KNNQGNGQGH NMPNDPNRNV DENANANNAV
KNNNNEEPSD KHIEQYLKKI KNSISTEWSP CSVTCGN-
GIQ VRIKPGSANK PKDELDYEND IEKKICKMEK CS) [20].
ELISA
The presence and level of antibodies to peptides corresponding to
the repeat region of the P. berghei,( D P P P P N P N ) 2,a n dP. falciparum,
NANP50, CSP proteins, or to the long peptides that span the N- and
C-termini of the CSP proteins from these two parasite species, were
determined by ELISA as described previously [23]. Briefly, 96-well
flat-bottom plates (Maxisorp, Nunc, Roskilde, Denmark) were
coated with 1 mg/ml in PBS, pH 7.8, by overnight incubation at
4uC. After extensive washes, the wells were blocked with 200 mlo f
PBS-Tween (PBS containing 0.05% Tween and 1% bovine serum
albumin) for 1 h. The wells were incubated overnight at 4uC with
100 ml mouse sera diluted 1/100 in PBS-Tween, then washed twice
and incubated for 45 min at room temperature, either with a Goat
anti-mouse IgM (Invitrogen SARL, Cergy Pontoise, France) or with
abiotinylated-goatanti-mouseIgG(JacksonImunoResearchEurope
Ltd, Newmarket, United Kingdom) diluted in PBS-Tween. The
wells containing the anti-IgM antibody were washed and further
incubated with a biotinylated rabbit anti-goat IgG (Sigma-Aldrich,
Saint-Quentin Fallavier, France) diluted in PBS-Tween for 45 min
at room temperature, then washed and incubated with extravidin-
coupled alkaline phosphatase (Sigma-Aldrich) diluted in PBS-Tween
1hatroom temperature. Phosphataseactivitywas measured using 4-
methylumbelliferyl phosphate (Sigma-Aldrich) as a substrate and the
fluorescence at 355/460 nm was measured using a spectrophotom-
eter (Victor 1420, Wallac Oy, Turku, Finland).
Immunofluorescence assay
Sera from mice immunized with irradiated sporozoites were tested
by immunofluorescence using air-dried methanol-fixed or unfixed
(‘‘wet’’) sporozoites from the different Plasmodium lines, in order to
detect total or surface antigen content as previously described [24].
ELISPOT assay
PVDF microplates (Millipore, Bedford, MA, USA) were coated
overnight at 4uC with 15 mg/ml of an anti-mouse IFN-c rat
monoclonal antibody (clone AN18, Mabtech AB, Sophia Anti-
polis, France) diluted in PBS. After extensive washes, the wells
were blocked with RPMI medium containing 10% foetal calf
serum for 2 h at 37uC. Spleen cells were incubated overnight with
one of the peptides corresponding to a specific epitope (final
concentration 10 mg/ml) and with 30 U/ml of recombinant
human IL2. The plates were then washed, incubated with 2 mg/
ml of biotinylated anti-mouse IFN-c rat monoclonal antibody
(clone R4-6A2, Mabtech AB) diluted in PBS containing 0.5%
bovine serum albumin for 2 h at 37uC, and then overnight at 4uC.
Plates were subsequently incubated with extravidin-coupled
alkaline phosphatase (Sigma-Aldrich) diluted in PBS. After adding
the BCIP/NBT substrate (Sigma-Aldrich), IFN-c spot forming
cells (SFC) were counted under a stereomicroscope and expressed
as the number of spots per million cells tested.
RESULTS AND DISCUSSION
Given the major differences between the sequences of the P. berghei
and P. falciparum CSP genes (Figure 1), we predicted that the
immune responses induced by immunisation with irradiated
CSP and Sterile Protection
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CSP. In this case, any protection observed in the immunised mice
challenged with the P. berghei [PfCS] parasites, would be due to
immune responses independent of CSP.
Groups of mice were immunized with three doses of irradiated
P. berghei sporozoites. Sterile protection in this gold standard model
is considered to depend on a combination of the antibody
responses induced against CSP, leading to sporozoite inactivation
and inhibition of hepatocyte invasion, and on the cellular
responses induced against CSP, leading to the destruction of
infected hepatocytes. Therefore, the immune responses induced
against the CSP in the immunised mice were carefully character-
ized. A set of long peptides spanning all the CD4 and CD8
epitopes present in the N- and C-terminal regions flanking the
central repeats of the P. berghei CSP [20,21] or the P. falciparum
CSP [19,20,22] were used to demonstrate that the T cell responses
induced by immunization with P. berghei were minimally cross-
reactive with the P. falciparum CSP (Figure 2). The IgG and IgM
antibodies induced by immunisation with P. berghei irradiated
sporozoites against the immunodominant central repeat region of
CSP were then assayed. Cross-reactive anti-CSP antibodies to the
P. falciparum CSP were undetectable or very low when assayed by
ELISA using peptides specific to the repeat regions of the two
proteins (Figures 2A and 2B). The bulk of the IgG response
directed against the homologous P. berghei sporozoites was
restricted to the CSP, corresponding to an IFAT titre of ,1/
51200 on wet sporozoites, and showed no reactivity of the
heterologous P. berghei [PfCS] sporozoites with titres equal or below
1/10 (Figure 2C). The levels of the IgM responses induced were
much lower than those of the IgG responses (Figure 2A), and most
of the cross-reactive IgM responses, IFAT titres of 1/100, were
directed against components other than the CSP (Figures 3B and
3C). The antibody responses in animals immunised only once with
P. berghei irradiated sporozoites were much lower, nonetheless the
same pattern of antibody reactivities was observed when their sera
were similarly assayed (data not shown).
Since minimal CSP cross-reactive responses are induced by
immunisation with wild type P. berghei irradiated sporozoites, if the
sterile protection induced were dependent on CSP-specific
immune responses, then the immunized mice should not be
protected against challenge with P. berghei [PfCS] sporozoites that
express a heterologous CSP. However, BALB/c mice immunized,
either once or three times, with P. berghei irradiated sporozoites
were found to be protected from infection whether challenged with
homologous sporozoites or with those from P. berghei [PfCS]
(Figure 4). These observations were not restricted to BALB/c mice
Figure 1. Comparison of the amino acid sequences of the P. berghei ANKA clone cy17 (34) and P. falciparum Welcome strain (35) CSP
polypeptides. Black dots represent identical amino acid residues while bars represent amino acid residues with similar characteristics. The repeat
regions (including the pre- and post-repeat sequences) are underlined.
doi:10.1371/journal.pone.0001371.g001
Figure 2. CSP-specific T cells induced by immunization with
irradiated P. berghei sporozoites do not cross-react with the P.
falciparum CSP expressed by the P. berghei [PfCS]. IFN-c ELISPOT was
used to determine the frequency of epitope-specific T cells in the
spleens of immunised animals, using long peptides corresponding to
the N-terminus (PbNt or PfNt) or the C-terminus (PbCt or PfCt) of P.
berghei and P. falciparum, respectively. Results are expressed as the
mean 6 SEM of T cells from groups of 5 mice.
doi:10.1371/journal.pone.0001371.g002
CSP and Sterile Protection
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P. berghei irradiated sporozoites and challenged with P. berghei
[PfCS] were also protected (Figure 5). These results demonstrate
that the acquisition of sterile immunity can be achieved
independently of the CSP-specific cellular and humoral responses
induced by immunization. Thus, it can be concluded that the
contribution of CSP is not essential to sterile protection.
Recently, a series of elegant experiments based on mice made
tolerant to the CSP of P. yoelii, another rodent malaria model [25]
led to deduce an immunodominant protective role for CSP, an
interpretation that contradicts the conclusions reported here. In
these experiments, the weight of CSP in protection was defined in
terms of reduced hepatic parasite burden (as measured by
quantitative RT-PCR), a measure not necessarily indicative of
sterile protection. Parasite burdens in CSP-tolerant mice immu-
nized with two doses of irradiated sporozoites were indeed 10 000
times higher than those observed in similarly treated control
animals. Nonetheless, when 3 immunizing doses were used, as was
the case in the investigations reported here, full protection against
sporozoite challenge was observed in the mice made tolerant to the
CSP, thus casting a doubt on a central role for CSP in sterile
immunity. Two possible reasons were put forward to account for
Figure 3. Antibody reactivity induced by immunization with irradiated sporozoites. Pooled serum samples from groups of mice immunized with
sporozoites from the different parasite lines were analyzed by ELISA to assay IgG and IgM responses induced against P. berghei CSP (A), or P.
falciparum CSP (B), using long peptides covering the N-terminus or the C-terminus of the antigen, and short peptides that include some of the repeat
units of the central repetitive region. Serums were also tested by IFAT against wet sporozoites to detect anti-CSP IgG and IgM antibodies(C). Titres are
expressed as the log of the highest dilution of serum giving a positive staining.
doi:10.1371/journal.pone.0001371.g003
CSP and Sterile Protection
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by the third immunizing dose, or second, a preponderant role for
non-CSP parasite antigens. The second view is consistent with the
powerful CD8
+ protective responses directed against non-CSP
antigens demonstrated in the CSP-tolerant mice [25], as well as
with our experimental observations obtained using normal mice
where the issue of immune tolerance does not apply.
In conclusion, despite the B cell immunodominance of CSP, we
demonstrate that the CSP-specific responses induced by immuni-
zation with irradiated sporozoites are not necessary to account for
the gold standard anti-malaria protection, i.e. prevention of the
blood stage infection. The fact that CSP is the major surface
protein of sporozoites which it covers entirely, associated to the
highly biased antibody responses directed against the sporozoite,
suggest that the CSP might play a significant role in immune
evasion: by monopolizing the host responses mounted against PE
parasites, the CSP would deviate the host defences away from
other antigens capable of acting as targets of the sterile protective
immunity, such as the one induced by immunization with
irradiated sporozoites. It is acknowledged that the conclusions
derived from investigations into the immunity against PE stages in
the rodent models are applicable to the situation in the human
infection [27,28]. Thus our data suggest that immunity induced
against P. falciparum CSP in humans might also be inadequate in
conferring sterile protection. This would explain the limited
efficacy of sub-unit CSP based vaccines [11]. Given the major
costs associated with the development and clinical testing of
vaccines against the pre-erythrocytic stages of P. falciparum, it might
be judicious to adopt the strategy presented here to other
candidates for which a homologue exists in parasites species that
infect rodents. Moreover, the search for the parasite antigens that
are actually implicated in the acquisition of sterile protection
should be strongly encouraged. Finally, our data illustrates the
value of using whole parasites in studies aimed at elucidating
malaria immunity, to the development of synthetic, subunit, or
practical live sporozoite vaccination strategies [29–33].
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